ArticleCirculation research2016
Age and Human Regenerative Capacity Impact of Cardiovascular Risk Factors.
Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 56 citations in OpenAlex.
- Circulating Progenitor Cells, Regenerative Capacity and Cognition: Evidence From 2 Community-Based Cohorts.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Quantitative Ultrasound Assessment of Skeletal Muscle Microvascularity in Relation to Serum 25-Hydroxyvitamin D Concentrations.Diagnostics (Basel, Switzerland) · 2026Article
- Mental stress as a trigger of cardiovascular events: A narrative review.European journal of clinical investigation · 2026Review
- Oncostatin M is dispensable for the regulation of hematopoietic stem/progenitor cell traffic by neutrophils.iScience · 2025Article
- Psychosocial stress and cardiovascular disease.American journal of preventive cardiology · 2025Review
- Stress and cardiovascular disease: an update.Nature reviews. Cardiology · 2024Review
- Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.International journal of cardiology · 2024Article
- Non-coding RNAs regulating endothelial progenitor cells for venous thrombosis: promising therapy and innovation.Stem cell research & therapy · 2024Review
- The association between circulating CD34+CD133+ endothelial progenitor cells and reduced risk of Alzheimer's disease in the Framingham Heart Study.Exploration of medicine · 2024Article
- Downregulation of miR-125a-5p Promotes Endothelial Progenitor Cell Migration and Angiogenesis and Alleviates Deep Vein Thrombosis in Mice Via Upregulation of MCL-1.Molecular biotechnology · 2023Article
- Article
- Circulating progenitor cells and outcomes in patients with coronary artery disease.International journal of cardiology · 2023Article
- The association between baseline circulating progenitor cells and vascular function: The role of aging and risk factors.Vascular medicine (London, England) · 2022Article
- Associations Between Inflammation, Cardiovascular Regenerative Capacity, and Cardiovascular Events: A Cohort Study.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- Associations between increased circulating endothelial progenitor cell levels and anxiety/depressive severity, cognitive deficit and function disability among patients with major depressive disorder.Scientific reports · 2021Article
- Brain-heart connections in stress and cardiovascular disease: Implications for the cardiac patient.Atherosclerosis · 2021Review
- Vascular Regenerative Capacity and the Obesity Paradox in Coronary Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- Transplantation of CD34+ cells for myocardial ischemia.World journal of transplantation · 2021Review
- Circulating stem cells and cardiovascular outcomes: from basic science to the clinic.European heart journal · 2020Review
- Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency.JACC. Basic to translational science · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
rationaleWe investigated aging of human endogenous reparative capacity and aimed to clarify whether it is affected by presence of cardiovascular disease or its risk factors (RFs).
objectiveCirculating progenitor cell (PC) levels reflect endogenous regenerative potential. The effect on PC of healthy aging compared with aging with RFs or cardiovascular disease (CVD) is unknown. We examined whether exposure to RF and CVD leads to an accelerated decline in circulating PC with increasing age. METHODS AND
resultsIn 2792 adult subjects, 498 were free of RFs (smoking, diabetes mellitus, hypertension, or hyperlipidemia), 1036 subjects had 1 to 2 RF, and 1253 had ≥3 RFs or CVD. PC were enumerated by flow cytometry as CD45(med+) mononuclear cells expressing CD34 and subsets coexpressing CD133, CXCR4, and vascular endothelial growth factor receptor-2 epitopes. Younger age, male sex, and larger body size correlated with higher PC counts (P<0.01). After multivariable adjustment, both age and RF categories were independently associated with PC counts (P<0.05), with lower PC counts in older subjects and those with higher RF burden or CVD. PC counts remained unchanged with increasing age in healthy individuals. There were significant interactions between age and RF categories (P≤0.005), such that for younger subjects (<40 years), RFs were associated with increased PC counts, whereas for older subjects (>60 years), RFs and CVD were associated with lower PC counts.
conclusionsCirculating PC levels do not decline with healthy aging; RF exposure at a younger age stimulates PC mobilization, whereas continued exposure is associated with lower PC levels in later life. Over the lifespan, exposure to RFs and CVD is associated with an initial stimulation and subsequent decline in circulating PC levels, which reflect endogenous regenerative capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.